PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Prescription medication · Angiotensin II Receptor Blocker (ARB)

azilsartan

Also sold as Edarbi.

Data updated 2026-05-15

3
InteractionsFew interactions
$7.61
Brand price (NADAC)

Drug Pricing (NADAC)

Brand Price

$7.61/unit

Generic Available

No

AZURITY

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

View Alternatives → Compare with Another Drug →

What it does

Information not available.

Common side effects

Dizziness, Fatigue

Key warnings

No specific warnings noted. Always follow your prescriber's instructions.

Known Drug Interactions

7.2 Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Do not coadminister aliskiren with Edarbyclor in patients with diabetes. Avoid use of aliskiren with Edarbyclor in patients with renal impairment (GFR <60 mL/min).

Mechanism: Both drugs block the same system that controls blood pressure, which can cause your blood pressure to drop too low and strain your kidneys. This can also lead to dangerously high potassium levels in your blood.

What to do: Do not take these together if you have diabetes or kidney problems. Your doctor will likely prescribe only one of these to protect your health.

7 DRUG INTERACTIONS Renal clearance of lithium is reduced by diuretics, such as chlorthalidone increasing the risk of lithium toxicity ( 7 ) NSAIDS increase risk of renal dysfunction and interfere with antihypertensive effect ( 7 ) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia ( 7 ) Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7 ) 7.1 Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including...

Mechanism: These drugs work in different ways to lower blood pressure, which can increase the risk of very low blood pressure and kidney problems.

What to do: Your doctor should monitor your blood pressure and kidney function closely while you are taking these medications.

moderate lithium

7 DRUG INTERACTIONS Renal clearance of lithium is reduced by diuretics, such as chlorthalidone increasing the risk of lithium toxicity ( 7 ) NSAIDS increase risk of renal dysfunction and interfere with antihypertensive effect ( 7 ) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia ( 7 ) Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7 ) 7.1 Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including...

Mechanism: Azilsartan can make it harder for the kidneys to remove lithium from the body. This causes lithium levels to build up, which can lead to dangerous side effects.

What to do: Your doctor should monitor your lithium blood levels closely. They may need to adjust your lithium dose while you are taking this medication.

This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.

Common Questions

What are the common side effects of azilsartan?
The most commonly reported side effects of azilsartan include Dizziness, Fatigue. Always consult your healthcare provider about potential side effects.
Does azilsartan interact with other medications?
Yes, azilsartan has 3 known drug interactions. Notable interactions include aliskiren, chlorthalidone, lithium. Always inform your doctor about all medications you are taking.
What drug class is azilsartan?
azilsartan belongs to the Angiotensin II Receptor Blocker (ARB) drug class. It requires a prescription (Rx).

Related Medications in Angiotensin II Receptor Blocker (ARB)

Other drugs grouped near azilsartan - same-class peers and common alternatives.

Compare azilsartan vs acebutolol side-by-side →

Medication Guides

Save on azilsartan

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for azilsartan

The FDA label for azilsartan (sold under brand names such as Edarbi) classifies it as a prescription-only medication in the Angiotensin II Receptor Blocker (ARB) class. Regulatory labeling describes its approved uses and the patient populations studied in pre-market trials. Official labeling lists 2 commonly reported side effects, including Dizziness, Fatigue.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. The database also lists 3 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.

Last updated: July 23, 2025

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

All federal data sources used on this page